CSI Market
Sign In | Register

Scilex Holding (SCLX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SCLX Annual Cash Flow →
Quarterly cash flow trends provide additional context on Scilex Holding's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-318.64
Depreciation & amortization5.71
Amortization of Other Assets6.20
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Bargain Purchase, Gain Recognized, Amount0.00
Provision For Loan Losses Expensed0.87
Increase (Decrease) in Inventories-0.62
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets-27.35
Share-based Compensation7.22
Income (Loss) from Equity Method Investments-82.45
Gains (Losses) on Extinguishment of Debt-0.43
Formation Cost Paid Through Advances From Affiliate Of Sponsor-
Interest And Dividend Income Securities Held To Maturity-
Loss On Initial Issuance Of Private Warrants-
Initial Classification Of Ordinary Shares Subject To Possible Redemption-
Loss On Initial Issuance Of Warrant Liability-
Notes Principal Increase-
Payment On The Scilex Pharma Notes Attributed To Accreted Interest Related To The Debt Discount-
Non Cash Operating Lease Cost0.64
Derivative Gain Loss On Derivative Net-25.71
Forfeitures Of Private Warrants-
Increase Decrease In Accrued Payroll0.63
Change In Fair Value Of Debt And Liability Instruments2.80
Realized Gain Loss On Digital Assets18.06
Non Cash Revenue-1.13
Gain From Kind Dividend-0.53
Income taxes0.00
Losses/ -gains on Investments net-85.51
Increase (Decrease) in Accounts Receivable-8.73
Accounts Payable-4.36
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expenses, Other1.00
Other Working Capital-2.66
Other Noncash Expense0.00
Other net-3.87
Payments for (Proceeds from) Other Operating Activities505.76
Discontinued operations0.00
Net Cash flow from Operating Activities-7.84
Investing Activities
Capital Expenditures-19.29
Sale of Capital Items0.02
Proceeds from Sale and Maturity of Marketable Securities2.95
Short-term Investments Acq.0.00
Real Estate Investments0.00
Purchase Of Convertible Promissory Note-
Acquisition Consideration Paid In Cash For Romeg Intangible Asset Acquisition-0.15
Purchase Of Patent-2.90
Repayments On Promissory Note-0.75
Purchase Of Preferred Shares Of Vivasor-0.30
Issuance Of Convertible Note Receivable-20.00
Sale Of Datavault A I Inc Shares For Cash31.39
Payment For Licenses-0.50
Restricted Cash and Investments Increase (Decrease)0.00
Payments to Acquire Leases Held-for-investment-0.50
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net16.12
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.71
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings-6.32
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock7.02
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock-2.38
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net10.57
Proceeds From Promissory Note Related Party-
Notes Issued-
Proceeds From Simple Promissory Note Related Party-
Repayment Of Promissory Note Related Party-
Proceeds From The Business Combination-
Transaction Costs Paid Related To The Recapitalization Transaction-
Repayment Of Principal On The Scilex Pharma Notes-
Proceeds From Repayment Of Loans To Purchase-
Disbursement Of Funds-
Accelerated Share Repurchases Adjustment To Recorded Amount-
Transaction Costs Paid In Connection With Share Repurchase-
Proceeds From Issuance Of Revolving Facility-
Repayment Of Revolving Facility-
Payments of Dividends, Preferred Stock and Preference Stock-4.23
Dividends paid0.00
Net Cash Flow from Financing Activities4.66
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-27.12
Total Cash Flow-4.39
4 historic quarters locked

Sign in to unlock the full Scilex Holding cash flow history.

Sign In Create Free Account

About Scilex Holding Co Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-352464

Figures are derived from filed reports and may be restated. Historical data is subject to revision.